1302 (1302) Fair Value & Analysis

Healthcare · Market cap HK$6.1B

1 1302 1302 · HK

PriceHK$1.38

Fair ValueHK$0.8500

Upside-38.4%

Quality56/100

Watch 1302 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$0.6600 – HK$1.07

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −14.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.36 – HK$2.29 · fair‑value band HK$0.6600 – HK$1.07 · the HK$1.38 price screens above the HK$0.8500 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1302 (1302) currently trades at HK$1.38, while our model-based Fair Value estimate is HK$0.8500 — implying the stock looks roughly 38.4% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1302 generated revenue of HK$1.4B at a net margin of 10.8%. Revenue grew 6.5% year over year. It earns a return on equity of 3.2%. The balance sheet holds a net cash position of HK$765M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.4B

Revenue growth (YoY) +6.5%

Net margin 10.8%

Return on equity 3.2%

Free cash flow HK$501M FY2025

P/E ratio 34.5

More key figures

Operating margin 23.8%

EPS (TTM) HK$0.0500

EPS growth (YoY) +413%

Net cash HK$765M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1302 reported revenue of HK$1.4B in FY2025 versus HK$925M in FY2021, a compound +10.3%/yr. Reported net income was HK$148M in FY2025, compounding −15.7%/yr from FY2021.

Revenue +10.3%/yr

FY21 HK$925M

FY22 HK$1.1B

FY23 HK$1.3B

FY24 HK$1.3B

FY25 HK$1.4B

Net income −15.7%/yr

FY21 HK$292M

FY22 HK$325M

FY23 HK$263M

FY24 HK$222M

FY25 HK$148M

Is 1302 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$39.41	R$30.42	-23%
Stryker Corporation S1YK34	R$79.18	R$43.78	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1302 (1302) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.8500 versus a price of HK$1.38 — about −38% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1302?

Our model-based fair value for 1302 is HK$0.8500 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.38.

What is the quality score of 1302?

1302 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1302 (1302)?

1302 reported trailing-twelve-month revenue of about HK$1.4B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1302?

The net profit margin of 1302 is about 10.8%, meaning it keeps roughly 10.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.